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Abstract In the brain, neurons and glial cells compete for the
uptake of the fast neurotransmitters, glutamate, GABA and
glycine, through speci¢c transporters. The relative contributions
of glia and neurons to the neurotransmitter uptake depend on
the kinetic properties, thermodynamic coupling and density of
transporters but also on the intracellular metabolization or se-
questration of the neurotransmitter. In the case of glycine,
which is both an inhibitory transmitter and a neuromodulator
of the excitatory glutamatergic transmission as a co-agonist of
N-methyl D-aspartate receptors, the glial (GlyT1b) and neuronal
(GlyT2a) transporters di¡er at least in three aspects: (i) stoi-
chiometries, (ii) reverse uptake capabilities and (iii) pre-steady-
state kinetics. A 3 Na+/1 Cl^/gly stoichiometry was established
for GlyT2a on the basis of a 2 charges/glycine £ux ratio and
changes in the reversal potential of the transporter current as a
function of the extracellular glycine, Na+ and Cl^ concentra-
tions. Therefore, the driving force available for glycine uphill
transport in neurons is about two orders of magnitude larger
than for glial cells. In addition, GlyT2a shows a severe limita-
tion for reverse uptake, which suggests an essential role of Gly-
T2a in maintaining a high intracellular glycine pool, thus facil-
itating the re¢lling of synaptic vesicles by the low a⁄nity, low
speci¢city vesicular transporter VGAT/VIAAT. In contrast, the
2 Na+/1 Cl^/gly stoichiometry and bi-directional transport prop-
erties of GlyT1b are appropriate for the control of the extra-
cellular glycine concentration in a submicromolar range that can
modulate N-methyl D-aspartate receptors e¡ectively. Finally,
analysis of the pre-steady-state kinetics of GlyT1b and GlyT2a
revealed that at the resting potential neuronal transporters are
preferentially oriented outward, ready to bind glycine, which
suggests a kinetic advantage in the uptake contest. 4 2002
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1. Transporters of recapture in slow and fast transmission have
di¡erent constraints
In the central nervous system of Vertebrates, di¡usion and
uptake of neurotransmitters by speci¢c transporters terminate
synaptic transmission at the notable exception of acetylcholine
which is hydrolyzed by acetylcholinesterase. Transporters of
recapture are located in glial cells and/or neurons and uptake
regulates the basal extracellular concentration and spillover of
neurotransmitters, thus limiting synaptic cross talk. Though
recapture is their principal mode of operation, transporters
are bi-directional molecular machines and may also behave
as a Ca2þ-independent source of neurotransmitters, depending
on the direction of the driving force.
Transporters belong to two families of secondary active
transporters (see reviews in [1,2]) with a distinct membrane
topology and an ionic requirement for Cl3 and Kþ ions [3].
The largest family is formed by Naþ/Cl3 coupled co-trans-
porters that share high sequence homologies in their 12 puta-
tive transmembrane segments. This family includes the mono-
amines transporters (DAT, NET and SERT) and multiple
isoforms for GABA (GAT1-4) and glycine (GlyT1-2) trans-
porters. The other family is formed by the ¢ve isoforms of
glutamate transporters (GLAST, GLT1, EAAC1, EAAT4-5,
see review in [4]). These transporters have an unusual mem-
brane topology of 8 transmembrane segments with one [5] or
two re-entrant loops [6] and are assembled in pentameric
structures [7]. Glutamate uptake is coupled to Naþ cotrans-
port and obligatory Kþ counter-transport [8,9].
Transporters of recapture play a central role for the volume
transmission of monoamines [10] as demonstrated by the psy-
chostimulant and anti-depressant e¡ects of DAT, NET and
SERT inhibitors such as cocaine, desipramine and £uoxetine
(Prozac0). Accordingly, the rate of clearance of dopamine
and norepinephrine from the extracellular space determined
by cyclic voltammetry are V300 times slower in DAT3=3
[11] and V6 times slower in NET3=3 knockout mice com-
pared to wild-type animals. In addition to this phasic recap-
ture role, monoamine transporters contribute to the homeo-
stasis of the neurotransmitter as revealed by the profound
metabolic changes observed in DAT3=3 knockout mice [12].
In contrast, the contribution of transporters to the time-
course of fast synaptic transmission and spillover of GABA,
glutamate and glycine is intensely debated [13^16]. Mathemat-
ical models using elaborated synapse geometries show that
di¡usion alone can achieve clearance of glutamate at central
synapses [17^19] when the di¡usion coe⁄cient is not arbitrari-
ly adjusted to slow the process [20]. In addition, the low turn-
over of amino acid neurotransmitter transporters expressed in
Xenopus oocytes (GAT: V5 Hz [21], EAAT2: V15 Hz [22],
GlyT1-2: V20 Hz [23]) suggests that each transporter may
not have a chance to eliminate more than one neurotransmit-
ter molecule during a typical V10 milliseconds inhibitory or
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excitatory post-synaptic current (IPSC or EPSC). Neverthe-
less, uptake inhibitors potentiate GABAergic and glutamater-
gic synaptic transmissions in brain slices [14,16,24^28] and
limit the spillover of glutamate [29,30] and the activation of
high-a⁄nity metabotropic receptors [31]. Recent experimental
evidences explain how glutamate transporters can bu¡er syn-
aptically released glutamate with sub-millisecond kinetics [24] :
(1) transporter densities are higher than previously envisaged
[32], with densities of up to 8500 glutamate transporters/Wm2
in the molecular layer of the cerebellum [33] ; (2) the synapse
size and geometry with the presence or not of surrounding
astrocyte processes greatly in£uence the di¡usion and spill-
over of neurotransmitters ([28] ; see review in [30,34]) ; (3) glial
and neuronal glutamate transporters have a 3 Naþ stoichiom-
etry [35,36] that develops a large driving force for uphill trans-
port; (4) multiple Naþ binding synchronizes transporters, al-
lowing a rapid binding of glutamate [37] ; (5) fast applications
of glutamate show that the translocation step of transporters
is much faster than the overall cycle and occurs on a sub-
millisecond time scale [38,39].
2. Glycine web: connecting excitation and inhibition
To appreciate the role of transporters of recapture in gly-
cine neurotransmission, it is necessary to summarize brie£y
the complex activity of glycine as a neurotransmitter and a
neuromodulator.
2.1. Glycine is an inhibitory transmitter in the adult mammalian
CNS
Glycine is one of the major inhibitory neurotransmitters in
spinal cord and brainstem interneurons of adult mammalian
central nervous systems (CNS; see historical and comprehen-
sive reviews in [40] and [41]). Evidence for glycine inhibition in
higher brain structures is elusive, but glycine IPSCs were re-
corded in Golgi cells, an interneuron of the granular layer of
the cerebellum [42], as well as in glycine-evoked inhibitory
responses in olfactory bulb neurons [43] and CA3 hippocam-
pal neurons [44,45]. Glycine hyperpolarizes post-synaptic neu-
rons by activating strychnine-sensitive, Cl3-permeable, ligand-
gated ionotropic receptors (GlyR) formed by the association
of 3 K and 2 L subunits [46,47]. During development and early
post-natal days, activation of glycine or GABA receptors de-
polarizes developing motoneurons (see reviews in [48,49]) until
the neuronal transporter KCC2 lowers the intracellular chlo-
ride concentration and shifts the Cl3 equilibrium potential
toward more hyperpolarized potentials [50,51]. These gly-
cine-evoked depolarizations may bring the post-synaptic neu-
ron to the spiking threshold [51], but an inhibition is often
observed because of the large shunting conductance due to
GlyR activation [51,52]. Evidence for a pre-synaptic localiza-
tion of strychnine-sensitive glycine receptors has been re-
ported in giant excitatory synapses (calyx of Held) of the
medial nucleus of the trapezoid body [53]. In these brainstem
slices from P10-P16 rats, application of glycine evoked a small
depolarization of the pre-synaptic terminal, potentiating glu-
tamatergic transmission [53].
A signi¢cant number of inhibitory synapses co-released gly-
cine and GABA by the same pre-synaptic inhibitory neuron as
¢rst established by Jonas and co-workers in pairs of spinal
interneurons [54] and widely con¢rmed since then [55^58].
This co-release of the two inhibitory transmitters is presum-
ably [59] a direct consequence of the lack of selectivity be-
tween GABA and glycine of the vesicular inhibitory amino
acid transporter VGAT/VIAAT [60,61], which is localized in
pre-synaptic terminals of GABAergic and glycinergic neurons
[62,63].
2.2. Glycine is a neuromodulator of excitatory transmission
Glycine is a neuromodulator of excitatory transmission as a
high-a⁄nity co-agonist with glutamate of N-methyl D-aspar-
tate (NMDA) receptors [64]. NMDA receptors are hetero-
oligomers formed by the association of NR1 subunits that
contain the glycine binding site, sometimes referred to as the
glycine B site (see review in [65]), with at least one of the four
NR2 subunits (A^D) that control the apparent a⁄nity of the
co-agonist site. In fact, the nature of the endogenous ligand of
the NMDA receptors co-agonist site is debated, and cumula-
tive evidence suggests that glycine and D-serine compete for
the same site [66].
Since no evidence for a mechanism of co-liberation of gly-
cine and glutamate has been reported, it is assumed that the
occupancy of the glycine co-agonist site relies on the resting
extracellular glycine ([Gly]e) and D-serine concentrations. At
present, speci¢c D-serine transporters have not been reported
and it is not clear how D-serine which is synthesized in astro-
cytes is exported out of the cell, then degraded or recaptured
from the extracellular space. Nevertheless, an action of D-ser-
ine or glycine requires in the ¢rst place that transporters are
able to lower [Gly]e to submicromolar levels in the synaptic
cleft. This has been established in a model system of co-ex-
pression in Xenopus oocytes [67] and in hippocampal slices
[68] and brainstem hypoglossal motoneurons [69].
2.3. Glycine activates a cation selective receptor and may be a
‘true’ excitatory transmitter
Finally a third, truly excitatory, cation-permeable receptor
for glycine was identi¢ed by the expression of NMDA recep-
tors composed of NR1 and NR3 A or B subunits in Xenopus
oocytes [70]. These novel NMDA receptor isoforms have
unique properties since they are not activated by glutamate,
not blocked by Mg2þ, are relatively Ca2þ impermeable and
are inhibited by D-serine [70]. D-Serine-sensitive glycine-
evoked action potentials were recorded in cultured cortical
neurons but direct con¢rmation in brain slices is sought.
2.4. Glycine interactions between inhibitory and excitatory
transmissions
In spinal cord, brainstem and cerebellum, glycinergic and
glutamatergic synapses form contiguous patches on the same
post-synaptic neuron. Thus glycine inhibitory receptors and
NMDA receptors can be in neighboring micro-environments.
An attractive hypothesis would be that spillover of synapti-
cally released glycine from an inhibitory neuron has the ca-
pacity to potentiate neighboring NMDA receptors.
3. How glycine transporters may interplay with phasic
inhibition and tonic neuromodulation of glycine
Biosynthesis of glycine, a non-essential amino acid without
stereoisomer, follows the ubiquitous one carbon metabolism
in spinal inhibitory neurons [71]. Changes in the relative ex-
pression of the mitochondrial bio-synthetic and degradation
enzymes, serine hydroxymethyltransferase and glycine cleav-
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age system, respectively, should increase glycine availability in
glycinergic neurons (see review in [72]). However, glycine ac-
cumulation in synaptic vesicles by the vesicular transporter
requires a high intracellular glycine concentration because of
the low a⁄nity (EC50V20 mM) and poor selectivity of
VGAT/VIAAT (see reviews in [59,73]), and it is not known
if the bio-synthetic machinery alone is able to deliver such
high glycine concentrations. At the other end of the concen-
tration range, modulation of NMDA receptors via their co-
agonist site requires that the synaptic glycine concentration is
kept in the submicromolar range, much lower than in the
cerebro-spinal £uid (CSF). Therefore, plasma membrane gly-
cine transporters may be important players for glycine homeo-
stasis if they have the capacity to adjust glycine concentra-
tions in the di¡erent intracellular and extracellular compart-
ments over a large dynamic scale.
Early investigations identi¢ed two Naþ- and Cl3-dependent
glycine-speci¢c transporters in rat brain vesicles [74] that dif-
Fig. 1. A: Topology of GlyT1b and GlyT2a. Amino-acids considered extracellular are shown in blue, intracellular in gray, in transmembrane
segments in orange. As all members of the Naþ/Cl3 coupled transporters, the two glycine transporters have 12-membrane-spanning segments
with intracellular N- and C-termini. The N-terminus of GlyT2a, with over 200 amino-acids, is unusually long. B: Determination of the charge
to glycine ratio. Xenopus oocytes are large cells that allow simultaneous measurement of the glycine uptake current under voltage-clamp and
the radio-labeled glycine uptake (left). Plotting the amount of charge (expressed in pmol of elementary charges) as a function of glycine uptake
reveals that the GlyT2a charge to glycine ratio is twice that of GlyT1b (potentials between 3120 mV and 0 mV, n=23 for GlyT2a, n=21 for
GlyT1b). Adapted from Ref. [98].
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fered in their sensitivity to the N-methyl derivative sarcosine
[75]. These observations were con¢rmed by the successive
cloning of two closely related members of the Naþ/Cl3
coupled transporter family (GlyT1 and GlyT2a) [76^78],
which show di¡erential sensitivity to sarcosine, a substrate
of GlyT1b [67] that does not interact with GlyT2a. Analysis
of the gene coding for GlyT1b reveals 3 N- (a,b,c) and 2
C- (d,e) terminus exons [76,77,79,80]. Five GlyT1 variants
(a,b,c,e,f) have been described [76,77,79,80] that are generated
by di¡erent combinations of N- and C- terminal exons (ad,
bd, cd, ae, be). Isoforms containing exon e are expressed only
in the retina and interact with the GABA receptor b1 subunit
[80]. A second GlyT2 isoform (GlyT2b), which di¡ers by ¢ve
amino acids in the N-terminal and does not transport glycine,
has also been reported [81]. GlyT2a has a long N-terminal
domain of 200 amino-acids which is not found in any other
member of the Naþ/Cl3 coupled transporters (Fig. 1A). When
this domain was used as a probe in yeast two-hybrid screen-
ing, a speci¢c interaction was found with Ulip6, an Unc-33-
like phosphoprotein that belongs to a family involved in sig-
naling cascades of axonal guidance [82].
Structure^function studies con¢rm that GlyT1 and GlyT2
share the landmark membrane topology of the Naþ/Cl3
coupled family (Fig. 1A, see review in [83]). Puri¢cation and
reconstitution assays of native glycine transporters suggested
that the protein was active as a monomer [75], which was
con¢rmed recently by surface labeling of GlyT1b and GlyT2a
in Xenopus oocytes [84]. Tra⁄cking of GlyT2 at the plasma
membrane is regulated by a direct interaction with the
SNARE protein syntaxin1a [85,86]. The genetic expression
of the di¡erent glial isoforms GlyT1a-c is regulated by di¡er-
ent promoter usage [87] and neuronal induction is needed [88].
In the brainstem auditory nucleus, GlyT2 expression during
development is associated with a shift between GABAergic to
glycinergic transmission [89,90].
The cellular and tissular expression of GlyT1 and GlyT2
match the complex glycine activity described above. GlyT1
staining is found in astrocytes while GlyT2 is a reliable
marker of glycinergic neurons [91^93] and is localized in
axon and terminal boutons [94] (Fig. 2). GlyT2 expression is
restricted to the inhibitory system [91,94] while GlyT1b is also
found in areas devoid of strychnine-sensitive receptors where
it can control the local glycine concentration under the satu-
rating level of the NMDA receptors co-agonist site [77,94]. In
the intact retina, neuronal expression of GlyT1 has been de-
scribed in amacrine cells and some bi-polar neurons [94,95]
but not in Mu«ller cells [96]. In the autonomic system, GlyT1b
has been reported in pre-synaptic terminals of cholinergic
neurons, facing microdomains of GlyRs that they can activate
by reverse uptake [97]. Expression of GlyT1 in neurons may
thus be correlated with a physiological non-vesicular release
of glycine ^ a task for which GlyT2 is doubly non-adapted,
due to its limitation in the reverse uptake mode and its ‘high-
er’ stoichiometry [98].
Fig. 2. Roles of glycine transporters. GlyT2a and GlyT1b both contribute to the control of the extracellular [Gly] at the glycinergic synapses
(1) and limit spillover to neighboring synapses (2). The more energetic coupling of GlyT2a allows the maintenance of a high [Gly] in pre-synap-
tic boutons, su⁄cient to allow VIAAT/VGAT to ¢ll the synaptic vesicles (3). The less energetic coupling of GlyT1b may even allow a glycine
shuttle between astrocytes and neurons, maximizing the recycling of released glycine toward neurons (4). At glutamatergic synapses containing
NMDA receptors, GlyT1b expressed in surrounding astrocytes are lowering the extracellular [Gly] under the saturating level of the co-agonist
site despite the high [Gly] of the CSF (5). However, depolarization of/concentration changes in the astrocytes may be su⁄cient to reverse
GlyT1b function and potentiate NMDA responses (6), alone or in addition to a D-serine release (7), which mechanism has not yet been estab-
lished. Adapted from Ref. [98].
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3.1. Pharmacology of glycine transporters
GlyT1 and GlyT2 show di¡erential pharmacological sensi-
tivity for sarcosine, ethanol [99] and the anti-depressant
amoxapine [100]. Low a⁄nity glycine uptake inhibitors such
as glycyldodecylamide [101] and amoxapine have been re-
ported for GlyT2 [100]. In addition, glycine uptake by the
glial transporter is inhibited by arachidonic acid [102] and
acidic pH [103].
The lack of speci¢c, reversible inhibitors of GlyT1 and
GlyT2 has impaired the analysis of the contribution of glycine
transporters to the physiology of inhibitory and excitatory
synaptic transmission because the manipulations were limited
to the removal of Naþ or the application of sarcosine or
D-serine [15,69,104]. However, high-a⁄nity speci¢c inhibitors
have recently been developed for GlyT1b [105,106] and GlyT2
[107,108]. GlyT1 inhibitors are expected to potentiate NMDA
receptors via their co-agonist site and may serve to alleviate
the negative symptoms of schizophrenia, which presumably
involve a reduced activity of NMDA receptors as shown in
animal models [109,110]. GlyT2 inhibitors may be helpful to
reduce pain if they are able to potentiate glycinergic inhibitory
transmission as GABA transporter inhibitors do for GABAer-
gic transmission [16].
GlyT1b inhibitors are irreversible on the timescale of an
hour and their mode of action is not fully understood [105,
111]. Nevertheless, these molecules are becoming useful tools
for blocking recombinant transporters expressed in Xenopus
oocytes [98,111] or native transporters in synaptosomes [112]
and brain slice preparations [68,113,114].
3.2. Electrophysiological characteristics of glycine transporters
Transporters of recapture are electrogenic, carrying at least
one net positive charge per transport cycle. Macroscopic re-
cording of these transport-related currents is an attractive
method for studying cloned transporters because of the con-
trol of the cell membrane potential which greatly in£uences
both the kinetic and energetic of transport. The millisecond
time-resolution of this technique is well within the duration of
synaptic transmission. However, it requires that transporters
are expressed at densities (s 106 for a typical mammalian
cell, s 109 for Xenopus oocytes) su⁄cient to overcome the
atoscopic current (10318^10317 A) generated by individual
transporters which may be di⁄cult to achieve or may produce
over-expression artefacts. The situation is even worse with
monoamine transporters, which have a typical turnover 10^
20 times lower than amino-acid transporters and generate
small macroscopic transporter currents [115,116]. In addition,
current and transport were found not be as tightly coupled as
¢rst predicted. Electrophysiological characterization of DAT
[117], NET [118], SERT [119], GAT [120] and EAAT [121]
indicated that tight coupling is more the exception than the
rule in both neurotransmitter transporters families [122].
Glycine uptake in vesicles isolated from rat brain or C6
cells was known to be Naþ-, Cl3- and voltage-dependent
with a minimal stoichiometry of 2 Naþ/1 Cl3/glycine that
predicted a charge coupling of +1 charge/glycine [123,124].
The electrogenicity of glycine uptake was con¢rmed by the
recording of glycine-evoked current under voltage-clamp in
HEK cells and Xenopus oocytes expressing GlyT1 and
GlyT2 [67,98,103,125]. Steady-state currents did not reverse
up to +50 mV and the current-voltage relationships were lin-
ear (GlyT1b) or quasi-linear (GlyT2) [98,125].
To measure directly the ionic coupling of the two glycine
transporters, Xenopus oocytes have a unique advantage over
all other expression system. Their gigantic size (V1-mm di-
ameter) allows one to measure simultaneously, under voltage-
clamp, radio-labeled uptake and substrate-evoked current on
the same cell (Fig. 1B). Plot of the charge (time-integral of the
glycine-evoked current) as a function of glycine uptake shows
a linear relationship for GlyT1b and GlyT2a over a wide
range of transporter expression and membrane potentials
(Fig. 1C, [98]). However, the slopes were di¡erent and the
ionic coupling of GlyT2a (+2.1 e/glycine) was twice that of
GlyT1b (+1.01 e/glycine) [98]. To test and rule out diverse
hypotheses about possible ionic coupling (3 Naþ ; Cl3 ; Cl3
exchange as proposed for GAT1 [126], glycine-evoked un-
coupled current as found for the Cl3 uncoupled conductance
of glutamate transporters [121]), the stoichiometries of
GlyT1b and GlyT2a were directly determined using a reversal
potential slope method developed by Zerangue and Kava-
naugh [35] to solve a long lasting controversy about the stoi-
chiometry of glutamate transporters.
If the current is tightly coupled to transport, the reversal
potential of the substrate-gated current (Einv) should corre-
spond to the equilibrium potential (ET) of the transporter
(i.e. zero net £ux condition). For a glycine transporter that
couples the transport of one glycine to n Naþ ions and m Cl3
ions, the reversal potential is given by the relation:
EinvWET ¼ 2:3RTðn3mÞF log
½Naþne ½Cl3me ½Glye
½Naþni ½Cl3mi ½Glyi
 
ð1Þ
(R, T and F have their usual meaning).
The reversal potential of the transporter current must vary
accordingly with the change in substrate concentrations. This
is a main operational di¡erence with the constant reversal
potential observed with ionotropic ligand-gated receptors/vol-
tage-gated channels. If the reversal potential of the substrate-
gated current remains constant when the substrate concentra-
tion is changed, as reported once with GAT1 [127], the most
likely explanation is that the recorded current is not actually
coupled to active transport [127,128].
The reversal potential slope method allows a direct deter-
mination of the stoichiometric factors n and m by measuring
the slope of Einv change as a function of log([Naþ]e),
log([Cl3]e and log([Gly]e). Under these conditions, Eq. 1 can
be simpli¢ed to a system of linear equations with the slope
proportional to the stoichiometric exponents. Experimentally
this method has ¢ve explicit requirements: (i) a non-trans-
ported uptake inhibitor should be available in order to sepa-
rate by subtraction transporter outward current from all en-
dogenous oocyte conductances; (ii) the approximation
EinvVET must be veri¢ed (i.e. the substrate should not acti-
vate uncoupled conductances) ; (iii) the transporter must be
able to work in uptake and reverse uptake modes (i.e. can
generate inward and outward current); (iv) the reversal po-
tential must be in an experimental accessible voltage range;
(v) the charge/substrate coupling should be measured directly
with radio-labeled substrate, but this limitation can be over-
come in mammalian cells using statistical analysis for the
possible stoichiometries [36].
Using speci¢c GlyT1b and GlyT2a inhibitors provided by
Organon [106,107], it was shown that glycine does not evoke
uncoupled current in GlyT1b- and GlyT2a-expressing oocytes,
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indicating that the approximation EinvVET holds for these
transporters [98]. However, the neuronal and glial transport-
ers present a major di¡erence in their ability to function in the
reverse uptake mode. GlyT1b generates an outward current
after a glycine intracellular load in Xenopus oocytes [98] and
produces glycine e¥ux in transfected cells [129] or in synap-
tosomes [112] while GlyT2 shows a strong limitation for e¥ux
unless all the co-transported substrates glycine, Naþ and Cl3
were injected at high concentrations into the oocyte cytoplasm
with a micropipet [98]. Using the intracellular injection meth-
od, it was possible to measure GlyT2a Einv and to analyze the
Einv slope as a function of the logarithm of the three co-sub-
strates [98]. The GlyT2a Einv slope as a function of log([Gly]e)
of GlyT2a was half that of GlyT1b, which con¢rmed that the
extra charge of Gly2a was thermodynamically coupled to
transport. The conclusion from these experiments was that
glycine uptake is energetically coupled to 2 Naþ and 1 Cl3
for GlyT1b and to 3 Naþ and 1 Cl3 for GlyT2a [98], a unique
stoichiometry among Naþ/Cl3 coupled transporters (at least,
for which it has been determined).
4. Why glycine transporters have di¡erent stoichiometries
4.1. Supplying VGAT with glycine
Glial and neuronal transporters compete for fast re-uptake
of glycine in a common extracellular environment that under-
goes large dynamic variations during synaptic transmission.
Their contribution to the phasic uptake depends on their rel-
ative capacity to bind and trap rapidly the neurotransmitter,
which in turn depends on kinetic parameters that are mostly
Naþ- and voltage-dependent, i.e. driving force-dependent.
The driving force for glycine uptake can be rewritten from
the thermodynamic equilibrium equation of transport using
the electrochemical ion gradients as follows:
ð2Þ
(ENa, ECl are the Nernst potentials for Naþ and Cl3, respec-
tively, Vm is the membrane potential and F the faraday’s
constant).
A di¡erence of one Naþ in ionic coupling implies that the
available driving force for glycine uptake for GlyT2a is two
orders of magnitude larger than for GlyT1b under physiolog-
ical conditions. Because GlyT1 and GlyT2 share a ‘common’
extracellular space in spinal cord and brainstem, it can be
stated that the thermodynamic equilibrium for both trans-
porters corresponds to the condition:
½Glyi;Neuron
½Glyi;Astrocyte ¼ 10
ENa3Vm
59
 
ð3Þ
where [Gly]i;Neuron and [Gly]i;Astrocyte are the intracellular gly-
cine concentrations in glycinergic neurons and astrocytes, re-
spectively. For simpli¢cation, ENa, ECl and Vm were assumed
to be equal in astrocytes and glycinergic neurons. The predic-
tion of Eq. (3) is in good agreement with the fact that glycin-
ergic neurons have a higher glycine content than astrocytes or
other types of neurons.
Considering a resting glycine concentration in the both gly-
cinergic and glutamatergic synaptic clefts of 0.1^0.2 WM that
Fig. 3. A⁄nities of glycine ‘receptors’ and transporters (left) and the comparison between these a⁄nities and the gradients that can be main-
tained by GlyT2a and GlyT1b if equilibrium is reached.
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is non-saturating for NMDA receptors, a coupling to 3 Naþ
allows GlyT2a to maintain a concentration of 20^40 mM in
the synaptic boutons, while a coupling to only 2 Naþ would
allow an intracellular concentration of only V1 mM, prob-
ably too low to ensure an e⁄cient ¢lling-up of synaptic
vesicles considering the low a⁄nity of VIAAT/VGAT (Fig.
3). On the other hand, this internal glycine concentration is
close to what has been reported for astrocytes, meaning that
GlyT1b is working close to equilibrium.
A more speculative hypothesis is that GlyT2a may deplete
glycine from the extracellular space down to a concentration
that forces GlyT1b to operate in reverse uptake mode, thus
producing a transcellular glycine £ux from astrocytes to neu-
rons, similar to the glutamate/glutamine shuttle. This would
allow a co-operative action of glial and neuronal transporters
to quickly lower extracellular glycine after synaptic release
while maximizing the amount of glycine ¢nally recaptured
by the neurons. The limitation in e¥ux observed with GlyT2a
also contributes to glycine accumulation, preventing a tempo-
rary reversal of transport during neuronal activity.
The additional Naþ gives another advantage to GlyT2a
over GlyT1b in the uptake contest. The higher voltage-depen-
dence of the protein rearrangements (zN=1.48 vs. zN=0.55 e0
for GlyT2a and GlyT1b, respectively [130]) favors an extra-
cellular orientation of the glycine binding site at negative po-
tentials, giving a kinetic advantage to the neuronal transport-
er. This may be particularly important in spaces with limited
di¡usion as in the vicinity of synapses as long as equilibrium
is not reached: a concentration of 1 WM in a synaptic cleft of
surface of 0.5U0.5 Wm and a 20 nm width corresponds to
only three molecules.
4.2. Gating NMDA receptors activation by GlyT1b activity: a
biological transistor
Indeed, the high compactness of brain structures, with an
estimated extra/intracellular volume ratio of 0.2, facilitates a
rapid extracellular depletion over a slow intracellular accumu-
lation by transporter, as the e¡ect of uptake in terms of con-
centration change depends on the volume ratio of the two
compartments. This depletion opposes the accumulation of
substrate observed in structures with high external/internal
volume ratio, such as synaptic vesicles, epithelia or in vitro
uptake preparations.
Glycine depletion produced by glycine transporters can be
demonstrated in a Xenopus oocyte model system, in which
GlyT1b and NMDA receptors are co-expressed [67].
NMDA receptors are used as a sensor of the local, juxtamem-
brane glycine concentration when the transporter is active or
blocked by speci¢c inhibitors. Application of submicromolar
glycine concentration (0.3 WM with 2 WM glutamate), a hun-
dred times below the transporter EC50, evokes only a small
response that increases when transporters are inactivated by
depolarization or 10 WM ORG24598 (Fig. 4). In a provocative
image, NMDA-receptor activation is here under the control
of glycine transporter activity.
In the CNS, considering an intraglial glycine concentration
of 2 mM, GlyT1b is working close to equilibrium. Thus, small
concentration/potential changes in its vicinity may reverse the
net glycine £ux. Astrocytes are usually considered to be
clamped at the equilibrium potential of Kþ. However, it has
been suggested that activation of AMPARs in glial cells by
glutamate may produce a depolarization and a rise in [Naþ]i
that could be su⁄cient to reverse GlyT1b [131]. AMPARs and
Fig. 4. Control of the NMDA response by GlyT1b activity in a co-expression system. Oocytes expressing GlyT1b were subsequently injected
with mRNA of the NMDA receptors NR1 and NR2B subunits. Application of 0.3 WM glycine and 2 WM glutamate evoked only a small re-
sponse in control conditions (black trace) at negative potentials, but a full response during and shortly after a depolarization to +40 mV, po-
tential for which glycine uptake is strongly reduced. When GlyT1b is blocked by the speci¢c inhibitor ORG24598, NMDA response occurs at
all potentials (blue trace).
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glutamate transporter currents activated by synaptic release of
glutamate have been recorded in situ in glial cells in the cer-
ebellum [132,133] and the hippocampus [134,135]. The ampli-
tude of the AMPA currents recorded in the Bergmann cells
are around 100 pA, which predicts a depolarization of V7
mV assuming a membrane resistance of 70 M6 [132]. The
extent of depolarization that may occur in unclamped cells
is not known and may be larger. Moreover, a rise in intra-
cellular Naþ following AMPAR activation by kainate is able
to block two of the glial Kþ conductances [136,137]. The de-
polarization and the change in intracellular Naþ concentra-
tion (which could reach the 20^40 mM range because of the
low intracellular volume of ¢ne astroglial processes) may ef-
fectively be su⁄cient to reverse GlyT1b locally.
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